You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMDV3100
Accession NumberDB05094
TypeSmall Molecule
GroupsInvestigational
DescriptionMDV3100 is a small molecule compound developed to treat hormone-refractory prostate cancer. MDV3100, which was rationally designed based on a breakthrough discovery, directly addresses a key mechanism that leads to prostate cancer cell death. MDV3100 may block both hormone-refractory and hormone-sensitive prostate cancer better than currently available therapies.
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationInvestigated for use/treatment in prostate cancer.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionMDV3100 is the lead development candidate from a library of approximately 170 small molecules licensed by Medivation. These molecules were rationally designed to treat hormone-refractory prostate cancer by inhibiting the androgen receptor (AR) in a different manner from currently approved AR antagonist drugs, which are ineffective in treating prostate cancers that have become hormone-refractory.
TargetKindPharmacological actionActionsOrganismUniProt ID
Androgen receptorProteinunknownNot AvailableHumanP10275 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentClear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer1
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentCarcinoma of the Prostate2
1Active Not RecruitingTreatmentCarcinoma of the Prostate / Hormone Refractory Prostate Cancer1
1Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
1Active Not RecruitingTreatmentPancreatic Cancers1
1CompletedNot AvailableDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHealthy Volunteers / Kidney Diseases / Pharmacokinetics of MDV31001
1CompletedBasic ScienceCarcinoma of the Prostate / Pharmacokinetics of Caffeine / Pharmacokinetics of Dextromethorphan1
1CompletedBasic ScienceCarcinoma of the Prostate / Pharmacokinetics of Enzalutamide1
1CompletedBasic ScienceCastration Resistant Prostate Cancer (CRPC) / Healthy Volunteers / MDV3100 / Relative Bioavailability1
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics of Enzalutamide1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of MDV31001
1CompletedBasic ScienceNormal Hepatic Function / Severe Hepatic Impairment1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureter Cancer / Urethra Cancer1
1RecruitingTreatmentCarcinoma of the Prostate1
1RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
1, 2CompletedTreatmentCarcinoma of the Prostate / Castration Resistant Prostate Cancer (CRPC) / Prostate Neoplasms1
1, 2Not Yet RecruitingTreatmentMetastatic Prostate Carcinoma / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2SuspendedTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate1
2Active Not RecruitingTreatmentAdvanced Breast Cancer / HER2 Amplified / Human Epidermal Growth Factor Receptor 2 (HER2)1
2Active Not RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
2Active Not RecruitingTreatmentAdvanced, Androgen Receptor Positive Triple Negative Breast Cancer1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCarcinoma of the Prostate3
2Active Not RecruitingTreatmentCarcinoma of the Prostate / Castration-Resistant Prostate Cancer (CRPC)1
2Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2Active Not RecruitingTreatmentProstatic Neoplasms1
2CompletedTreatmentCarcinoma of the Prostate1
2Not Yet RecruitingTreatmentCancer, Breast2
2RecruitingSupportive CareAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2RecruitingTreatmentAdenocarcinoma of the Prostate1
2RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCarcinoma of the Prostate3
2RecruitingTreatmentCastration Resistant Prostate Cancer (CRPC) / Prostate Carcinoma Metastatic to the Bone1
2RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Cancer1
2RecruitingTreatmentEndometrial Cancers1
2WithdrawnTreatmentCarcinoma of the Prostate / Localized Prostate Cancer1
2WithdrawnTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentProgressive Metastatic Prostate Cancer1
3RecruitingTreatmentCancer of the PROSTATE / Carcinoma of the Prostate / Hormone Sensitive Prostate Cancer1
3RecruitingTreatmentCancer of the PROSTATE / Carcinoma of the Prostate / Nonmetastatic Castration-Resistant Prostate Cancer1
3RecruitingTreatmentCancer, Breast1
4Active Not RecruitingTreatmentCarcinoma of the Prostate1
4Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
4Active Not RecruitingTreatmentMetastatic Castration-Resistant Prostate Cancer (mCRPC)1
4RecruitingTreatmentCarcinoma of the Prostate1
Not AvailableApproved for MarketingNot AvailableMetastatic Castration Resistant Prostate Cancer1
Not AvailableRecruitingNot AvailableAdenocarcinoma, Prostate / Castration Levels of Testosterone / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Metastatic Prostatic Adenocarcinoma / Recurrent Prostate Cancer / Recurrent Prostate Carcinoma / Stage III Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentRecurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:
AR
Uniprot ID:
P10275
Molecular Weight:
98987.9 Da
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24